Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 20/20 | 1.00 |
| ▸ | PDGFRA | P16234 | 2/20 | 1.00 |
| ▸ | KIT | P10721 | 1/20 | 1.00 |
| ▸ | FGFR1 | P11362 | 1/20 | 1.00 |
| ▸ | FGFR2 | P21802 | 1/20 | 1.00 |
| ▸ | FGFR4 | P22455 | 1/20 | 1.00 |
| ▸ | FGFR3 | P22607 | 1/20 | 1.00 |
| ▸ | FLT3 | P36888 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2923829 | 0.96 | PDGFRB (1.00) | PDGFRBPDGFRAKITFGFR1FGFR2 | |
| SCHEMBL2921252 | 0.95 | PDGFRB (1.00) | PDGFRBPDGFRAKITFGFR1FGFR2 | |
| SCHEMBL2921098 | 0.95 | PDGFRB (1.00) | PDGFRBPDGFRAKITFGFR1FGFR2 | |
| SCHEMBL2914141 | 0.94 | PDGFRB (1.00) | PDGFRBPDGFRAKITFGFR1FGFR2 | |
| SCHEMBL2923097 | 0.94 | PDGFRB (1.00) | PDGFRBPDGFRAKITFGFR1FGFR2 | |
| SCHEMBL2922440 | 0.94 | PDGFRB (0.89) | PDGFRBPDGFRAKITFGFR1FGFR2 | |
| SCHEMBL2923657 | 0.94 | PDGFRB (1.00) | PDGFRBPDGFRAKITFGFR1FGFR2 | |
| SCHEMBL13330456 | 0.93 | PDGFRB (1.00) | PDGFRBPDGFRAKITFGFR1FGFR2 | |
| SCHEMBL2922350 | 0.92 | PDGFRB (1.00) | PDGFRBPDGFRAKITFGFR1FGFR2 | |
| SCHEMBL13330494 | 0.92 | PDGFRB (1.00) | PDGFRBPDGFRAKITFGFR1FGFR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170172989-A1 | TREATMENT OF CANCERS HAVING RESISTANCE TO CHEMOTHERAPEUTIC AGENTS | BAYER HEALTHCARE LLC (US) | 2017-06-22 | — | — | US | claimed |
| US-20100173954-A1 | TREATMENT OF CANCERS HAVING RESISTANCE TO CHEMOTHERAPEUTIC AGENTS | BAYER HEALTHCARE LLC (US) | 2010-07-08 | — | — | US | claimed |
| EP-2114403-A2 | TREATMENT OF CANCERS HAVING RESISTANCE TO CHEMOTHERAPEUTIC AGENTS | Bayer Healthcare, LLC (US) | 2009-11-11 | — | — | EP | claimed |
| WO-2008089388-A2 | TREATMENT OF CANCERS HAVING RESISTANCE TO CHEMOTHERAPEUTIC AGENTS | BAYER HEALTHCARE LLC (US) | 2008-07-24 | — | — | WO | claimed |
| US-10308943-B2 | Compositions with improved intravitreal half-life and uses thereof | VITRISA THERAPEUTICS, INC. (US) | 2019-06-04 | — | — | US | disclosed |
| EP-3414330-A1 | COMPOSITIONS WITH IMPROVED INTRAVITREAL HALF-LIFE AND USES THEREOF | Vitrisa Therapeutics, Inc. (US) | 2018-12-19 | — | — | EP | disclosed |
| US-20180340179-A1 | COMPOSITIONS WITH IMPROVED INTRAVITREAL HALF-LIFE AND USES THEREOF | SILICON VALLEY BANK | 2018-11-29 | — | — | US | disclosed |
| WO-2018148333-A1 | COMPOSITIONS WITH IMPROVED INTRAVITREAL HALF-LIFE AND USES THEREOF | VITRISA THERAPEUTICS, INC. (US) | 2018-08-16 | — | — | WO | disclosed |
| US-20180000771-A1 | AGENT FOR PREVENTING AND/OR TREATING AMYOTROPHIC LATERAL SCLEROSIS | KYOTO UNIVERSITY (JP) | 2018-01-04 | — | — | US | disclosed |
| WO-2017139417-A1 | COMPOSITIONS WITH IMPROVED INTRAVITREAL HALF-LIFE AND USES THEREOF | VITRISA THERAPEUTICS, INC. (US) | 2017-08-17 | — | — | WO | disclosed |
| US-20170172989-A1 | TREATMENT OF CANCERS HAVING RESISTANCE TO CHEMOTHERAPEUTIC AGENTS | BAYER HEALTHCARE LLC (US) | 2017-06-22 | — | — | US | disclosed |
| US-20130079246-A1 | Methods and Tools for Screening Agents Exhibiting an Activity on Receptors of the Tumor Necrosis Factor Receptor Superfamily | ADDEX PHARMA SA (CH) | 2013-03-28 | — | — | US | disclosed |
| WO-2007059155-A1 | TREATMENT OF CANCERS HAVING RESISTANCE TO CHEMOTHERAPEUTIC AGENTS | BAYER PHARMACEUTICALS CORPORATION (US) | 2007-05-24 | — | — | WO | disclosed |
| US-6750218-B2 | INHIBITORY ACTIVITY ON PHOSPHORYLATION OF PLATELET-DERIVED GROWTH FACTOR (PDGF) RECEPTOR USEFUL FOR THE TREATMENT OF CELL-PROLIFERATIVE DISEASES SUCH AS ARTERIOSCLEROSIS, VASCULAR REOBSTRUCTION, CANCER AND GLOMERULOSCLEROSIS | MILLENNIUMIUM PHARMACEUTICALS, INC. | 2004-06-15 | — | — | US | disclosed |
| US-20030229077-A1 | Nitrogen-containing heterocyclic compounds | MATSUNO KENJI (JP) | 2003-12-11 | — | — | US | disclosed |
| US-6472391-B2 | INHIBIT PHOSPHORYLATION OF PDGF RECEPTOR TO HINDER ABNORMAL CELL GROWTH AND CELL WANDERING; TREATMENT OF CELL-PROLIFERATIVE DISEASES SUCH AS ARTERIOSCLEROSIS, VASCULAR REOBSTRUCTION, CANCER AND GLOMERULOSCLEROSIS. | MILLENNIUM PHARMACEUTICALS, INC. | 2002-10-29 | — | — | US | disclosed |
| US-20020068734-A1 | Nitrogen-containing heterocyclic compounds | MILLENNIUM PHARMACEUTICALS, INC. | 2002-06-06 | — | — | US | disclosed |
| US-6207667-B1 | USEFUL FOR THE TREATMENT OF CELL-PROLIFERATIVE DISEASES SUCH AS ARTERIOSCLEROSIS, VASCULAR REOBSTRUCTION, CANCER AND GLOMERULOSCLEROSIS | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2001-03-27 | — | — | US | disclosed |
| US-6169088-B1 | FOR THE PREVENTION OR TREATMENT OF CELL-PROLIFERATIVE DISEASES SUCH AS ARTERIOSCLEROSIS, VASCULAR REOBSTRUCTION, CANCER AND GLOMERULOSCLEROSIS | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2001-01-02 | — | — | US | disclosed |
| EP-0882717-A1 | NITROGENOUS HETEROCYCLIC COMPOUNDS | KYOWA HAKKO KOGYO KABUSHIKI KAISHA (JP) | 1998-12-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180340179-A1 | COMPOSITIONS WITH IMPROVED INTRAVITREAL HALF-LIFE AND USES THEREOF | UACA, CRYAA, CRYAB | PDGFRB 1282/4885PDGFRA 1584/4885KIT 4338/4885 |
| US-20030229077-A1 | Nitrogen-containing heterocyclic compounds | ERBB4, NPR1, PDGFRB | PDGFRB 3/4885PDGFRA 5/4885KIT 2045/4885 |
| US-20020068734-A1 | Nitrogen-containing heterocyclic compounds | PDGFRB, MKI67, PDGFRA | PDGFRB 1/4885PDGFRA 3/4885KIT 1535/4885 |
| US-20180000771-A1 | AGENT FOR PREVENTING AND/OR TREATING AMYOTROPHIC LATERAL SCLEROSIS | WEE2, WEE1, ERBB2 | PDGFRB 40/4885PDGFRA 293/4885KIT 407/4885 |
| US-20170172989-A1 | TREATMENT OF CANCERS HAVING RESISTANCE TO CHEMOTHERAPEUTIC AGENTS | CDK4, TP53, ABCC1 | PDGFRB 2508/4885PDGFRA 2125/4885KIT 1281/4885 |
| US-10308943-B2 | Compositions with improved intravitreal half-life and uses thereof | UACA, CRYAA, CRYAB | PDGFRB 1282/4885PDGFRA 1584/4885KIT 4338/4885 |
| US-20100173954-A1 | TREATMENT OF CANCERS HAVING RESISTANCE TO CHEMOTHERAPEUTIC AGENTS | CDK4, TP53, ABCC1 | PDGFRB 2508/4885PDGFRA 2125/4885KIT 1281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.